Trial Profile
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Trastuzumab (Primary) ; Carboplatin
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Jun 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Aug 2012 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 14 Jun 2010 Primary endpoint results published in Cancer